2024
The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer
Johnson K, Ni A, Quiroga D, Pariser A, Sudheendra P, Williams N, Sardesai S, Cherian M, Stover D, Gatti-Mays M, Ramaswamy B, Lustberg M, Jhawar S, Skoracki R, Wesolowski R. The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer. Npj Breast Cancer 2024, 10: 49. PMID: 38898072, PMCID: PMC11187074, DOI: 10.1038/s41523-024-00652-4.Peer-Reviewed Original ResearchInvasive disease-free survivalHER2+ breast cancerAdjuvant trastuzumabOverall survivalLocoregional therapyUnivariate analysisBreast cancerBenefit of adjuvant trastuzumabBenefits of adjuvant systemic therapyMulti-institutional retrospective analysisAdjuvant systemic therapyCompare survival outcomesDisease-free survivalTrastuzumab monotherapyNode-negativeSystemic therapyCombination therapySurvival benefitStatistically significant improvementSurvival outcomesRetrospective analysisMultivariate analysisPrimary outcomeTrastuzumabTherapy
2022
Targetable genomic mutations in young women with advanced breast cancer.
Ansari N, Gao L, Sokol E, Sivakumar S, Huang R, Pelletier M, Levy M, Pavlick D, Danziger N, Ross J, Lustberg M, Rozenblit M. Targetable genomic mutations in young women with advanced breast cancer. Journal Of Clinical Oncology 2022, 40: 1027-1027. DOI: 10.1200/jco.2022.40.16_suppl.1027.Peer-Reviewed Original ResearchComprehensive genomic profilingTumor mutational burdenAdvanced breast cancerPD-L1 expressionBreast cancerYoung womenImmune therapyPIK3CA mutationsGenomic alterationsTumor cell PD-L1 expressionClasses of GAsRB1 mutationsDisease-free survivalActionable genomic alterationsDifferent mutational profilesPARP inhibitor useImmunotherapy optionsInhibitor useFoundation MedicineLymph nodesWorse prognosisBRCA2 mutationsEstrogen receptorMutational burdenOlder women
2020
A phase Ib study of the safety and pharmacology of nilotinib to prevent paclitaxel-induced peripheral neuropathy in patients with breast cancer.
Adams E, Lustberg M, Jin Y, Li Y, Sparreboom A, Hu S. A phase Ib study of the safety and pharmacology of nilotinib to prevent paclitaxel-induced peripheral neuropathy in patients with breast cancer. Journal Of Clinical Oncology 2020, 38: tps12128-tps12128. DOI: 10.1200/jco.2020.38.15_suppl.tps12128.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyPaclitaxel infusionFree survivalPeripheral neuropathyBreast cancerPaclitaxel-induced peripheral neuropathyBreast cancer stage IEarly-stage breast cancerGrade 2 neuropathyPhase Ib studyPhase II doseDisease-free survivalCancer stage IStage breast cancerBreast cancer therapyTyrosine kinase inhibitorsQuality of lifeOrganic anion transportingOATP1B1 inhibitionOral nilotinibWeekly paclitaxelPaclitaxel dosePaclitaxel therapyOverall survivalWeekly doses
2019
Survival outcomes by hormone receptor expression in early-stage HER2-positive breast cancer.
Sardesai S, Kassem M, Morgan E, Palettas M, Stephens J, Williams N, Stover D, Van Deusen J, Wesolowski R, Lustberg M, Ramaswamy B. Survival outcomes by hormone receptor expression in early-stage HER2-positive breast cancer. Journal Of Clinical Oncology 2019, 37: e12050-e12050. DOI: 10.1200/jco.2019.37.15_suppl.e12050.Peer-Reviewed Original ResearchDisease-free survivalPositive breast cancerHormone receptor expressionOverall survivalBreast cancerReceptor expressionPositive diseaseTumor gradeEarly-stage HER2-positive breast cancerOhio State University Comprehensive Cancer CenterSecond primary breast cancerSingle-institution retrospective analysisHER2-positive breast cancerAdjuvant ovarian suppressionHR-negative diseaseHR-negative patientsHR-positive diseaseTriple-positive diseaseAnti-estrogen therapyComplete pathologic responseSingle institution experienceKaplan-Meier methodPrimary breast cancerInvasive ductal cancerLow tumor gradeThe Global POLAR program: Two pivotal placebo-controlled studies of calmangafodipir used on top of modified FOLFOX6 to prevent chemotherapy-induced peripheral neuropathy (CIPN).
Lustberg M, Pfeiffer P, Qvortrup C, Muro K, Bengtson M, Nittve M, Sonesson C, Nagahama F, Sonehara Y, Carlsson C. The Global POLAR program: Two pivotal placebo-controlled studies of calmangafodipir used on top of modified FOLFOX6 to prevent chemotherapy-induced peripheral neuropathy (CIPN). Journal Of Clinical Oncology 2019, 37: tps3616-tps3616. DOI: 10.1200/jco.2019.37.15_suppl.tps3616.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyChronic chemotherapy-induced peripheral neuropathyMetastatic colorectal cancerProportion of patientsFree survivalSafety endpointCumulative doseHigh-risk stage IIAdditional safety endpointsProgressive-free survivalCommon adverse eventsPlacebo-controlled studyDisease-free survivalOxaliplatin-induced neuropathyTreatment of patientsManganese superoxide dismutase activitySuperoxide dismutase mimeticFOLFOX6 chemotherapyMFOLFOX6 chemotherapyOXA treatmentPrimary endpointAdverse eventsFirst doseOverall survivalMS patientsThe Global POLAR program: Calmangafodipir used on top of modified FOLFOX6 (5-FU/FA and oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN).
Pfeiffer P, Qvortrup C, Muro K, Lustberg M, Nagahama F, Sonehara Y, Bengtson M, Nittve M, Sonesson C, Carlsson C. The Global POLAR program: Calmangafodipir used on top of modified FOLFOX6 (5-FU/FA and oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN). Journal Of Clinical Oncology 2019, 37: tps722-tps722. DOI: 10.1200/jco.2019.37.4_suppl.tps722.Peer-Reviewed Original ResearchMetastatic colorectal cancerProportion of patientsFree survivalSafety endpointCumulative doseHigh-risk stage IIAdditional safety endpointsProgressive-free survivalCommon adverse eventsOxaliplatin-induced neuropathyDisease-free survivalPatient reported symptomsTreatment of patientsManganese superoxide dismutase activitySuperoxide dismutase mimeticFOLFOX6 chemotherapyMFOLFOX6 chemotherapyOXA treatmentPrimary endpointAdverse eventsFirst doseOverall survivalMS patientsPeripheral neuropathyTreatment breaks